Dr Sorensen is currently board director, president and CEO of Ascenta Therapeutics. Dr Sorensen is an experienced leader and administrator in cancer therapeutics and cancer drug development.
John Kovach, CEO of Lixte Biotechnology Holdings, said: “Mel is internationally recognized for his expertise in clinical oncology and in meeting the challenges of cancer drug development.
“In addition to his depth of knowledge and experience in applied cancer research, he has demonstrated remarkable administrative skills in bringing together the expertise of the diverse groups needed for the effective and safe development of important new anticancer drugs.”